It has been reported that biglycan is overexpressed in various cancers and correlates with progression, metastasis, and angiogenesis of gastric cancer, endometrial cancer, prostate cancer, and bladder cancer [26–31]. This evidence concerns the gene BGN and urinary bladder carcinoma.